MWNA
FLGT icon

Marshall Wace North America’s Fulgent Genetics FLGT Stock Holding History

Marshall Wace North America’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$930K Buy
+10,333
New +$939K ﹤0.01% 947
2021
Q2 		– Sell
-4,764
Closed -$461K – 1559
2021
Q1 		$461K Sell
4,764
-54,530
-92% -$5.63M ﹤0.01% 1218
2020
Q4 		$3.09M Buy
+59,294
New +$2.48M 0.01% 648

Other funds holding FLGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Marshall Wace North America's FLGT Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Fulgent Genetics (FLGT) in Q3 2021: 10,333 shares worth $930K. The stake represents ﹤0.01% of the portfolio and ranks #947 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in FLGT as recently as Q1 2021.

Marshall Wace North America first reported a position in FLGT in Q4 2020 and has held it in 3 quarters since. The position peaked at $3.09M in Q4 2020. 268 funds tracked by Wall St. Rank hold FLGT as of Q3 2021.

  • Marshall Wace North America held 10,333 shares of Fulgent Genetics worth $930K as of Q3 2021.
  • Fulgent Genetics was a new Marshall Wace North America position in Q3 2021.
  • Fulgent Genetics made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #947 holding.
  • Marshall Wace North America first reported a position in Fulgent Genetics in Q4 2020 and has held it in 3 quarters since.
  • Marshall Wace North America's Fulgent Genetics position peaked at $3.09M in Q4 2020.
  • 268 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.